<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750501</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 0000498-02</org_study_id>
    <nct_id>NCT02750501</nct_id>
  </id_info>
  <brief_title>Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study</brief_title>
  <acronym>ASSURE</acronym>
  <official_title>Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study in Patients With Cystic Fibrosis Receiving Enteral Feeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcresta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcresta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol 0000498: Multicenter, open label study to evaluate the effect of sustained RELiZORB
      (immobilized lipase) cartridge use during enteral feeding on fat absorption, as well as
      safety and tolerability of sustained RELiZORB use, in patients with cystic fibrosis and
      exocrine pancreatic insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Entry (Day -14): Baseline blood samples collected for plasma and erythrocyte
      concentrations of docosahexaenoic acid (DHA) and eicosapentaenoic (EPA). Baseline
      characteristics collected included BMI and cystic fibrosis related diabetes.

      Observation Period (Day -14 to Day -8): Subjects followed their usual enteral nutrition
      regimen with pancreatic enzyme replacement therapy (PERT).

      Run-in Period (Day -7 to Day -1): Subjects used Peptamen 1.5 enteral formula at their normal
      volume of administration from 500 mL to 1,000 mL per feeding with usual PERT regimen.

      Treatment Period (Day 0 to Day 90): Subjects used Impact Peptide 1.5 up to a maximum volume
      of 1,000 mL per feeding with RELiZORB for the 90 day treatment period. Blood screening
      measurements were repeated at start of treatment period (Day 0), Day 30, Day 60 and Day 90.
      PERT use with enteral feedings was prohibited. Safety and tolerability were assessed with GI
      symptom diaries and systematic assessments of adverse events and unanticipated adverse device
      effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2016</start_date>
  <completion_date type="Actual">March 30, 2017</completion_date>
  <primary_completion_date type="Actual">March 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA)</measure>
    <time_frame>Day 0 to Day 90</time_frame>
    <description>Change from baseline Day 0 to Day 90 of erythrocyte tissue composition % of the omega-3 index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unanticipated Adverse Device Effects (UADE)</measure>
    <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days with additional 30 days of follow up.</time_frame>
    <description>A UADE is analogous to a serious adverse event (SAE), defined as an AE, occurring at any exposure to the therapeutic agent, that results in any of the following outcomes: death, life-threatening AE, inpatient hospitalization or prolonged existing hospitalization, a persistent or significant disability or incapacity or a congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Plasma Concentration Total DHA+EPA</measure>
    <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
    <description>Changes in plasma concentration total DHA+EPA from baseline (Day 0 to Day 90).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Composition (%) of DHA</measure>
    <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
    <description>Changes over time in erythrocyte composition (%) for total DHA in ITT population (n=39)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Composition (%) of EPA</measure>
    <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
    <description>Changes over time in erythrocyte composition (%) for EPA in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Composition (%) Ratio of n6/n3 Fatty Acids</measure>
    <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
    <description>Change from baseline to Day 90 in n6/n3 ratio in erythrocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Composition (%) Ratio of n6/n3 Fatty Acids.</measure>
    <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
    <description>Change over time in n6/n3 ratio in plasma in the ITT population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>GI Symptoms</measure>
    <time_frame>Observation, Baseline and RELiZORB Treatment periods (Day -14 to Day 90): 104 days with additional 30 days of follow up.</time_frame>
    <description>GI symptoms recorded in GI diaries by subject and/or caregiver.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Single Arm: Open label RELiZORB Cartridge &amp; Impact Peptide 1.5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RELiZORB (immobilized lipase) cartridge</intervention_name>
    <description>Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge</description>
    <arm_group_label>Single Arm: Open label RELiZORB Cartridge &amp; Impact Peptide 1.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Impact Peptide 1.5</intervention_name>
    <description>Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding</description>
    <arm_group_label>Single Arm: Open label RELiZORB Cartridge &amp; Impact Peptide 1.5</arm_group_label>
    <other_name>Enteral Formula</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of cystic fibrosis

          2. Documented history of exocrine pancreatic insufficiency

          3. Enteral formula use a minimum of 4x/week, using PERT, consuming an unrestricted fat
             diet, and willing to use Peptamen 1.5 and Impact Peptide 1.5

          4. Written informed consent or assent.

        Exclusion Criteria:

          1. Uncontrolled diabetes mellitus

          2. Signs and symptoms of liver cirrhosis or portal hypertension

          3. Lung or liver transplant

          4. Active cancer currently receiving cancer treatment

          5. Crohn's or celiac disease, infectious gastroenteritis, sprue, lactose intolerance,
             inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhumalli Sarkar, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alcresta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joe DiMaggio Children's Hospital / Memorial Healthcare System</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's CF Center of Idaho</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital CF Care Center</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital / Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404-1815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <results_first_submitted>March 30, 2018</results_first_submitted>
  <results_first_submitted_qc>June 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2018</results_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CF, EPI, diabetes, PERT, LCPUFA, DHA, EPA, Omega-3 index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02750501/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02750501/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted through Cystic Fibrosis Care Centers.</recruitment_details>
      <pre_assignment_details>7-day Observation Period: Maintain usual enteral feeding (EF) regimen. 7-day Run-in period: Maintain usual EF volume up to a max of 1000 mL using standard formula for at least 5 days.
49 subjects signed consent; 5 screen failed; 44 started the observation period; 39 completed observation and run-in periods entering the treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Arm: Open Label</title>
          <description>49 subjects signed consent and were screened for the study. 44 subjects were eligible at time of screening. 39 subjects entered the treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>G-tube came out</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant use of PERT</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm: Open Label</title>
          <description>RELiZORB cartridge and Impact Peptide 1.5 with enteral feeding 500 mL to 1,000 mL per enteral feeding for a period of 90 days.
RELiZORB: Novel enteral feeding in-line digestive enzyme cartridge
Impact Peptide 1.5: Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte omega-3 index %</title>
          <population>ITT was 39, missing sample data due to one subject discontinuing prior Visit 3 therefore analysis population: N=38
Erythrocyte omega-3 index % measures erythrocyte membrane composition (%) of DHA+EPA.</population>
          <units>% of omega-3 index of RBC membrane</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.43" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>BMI formula: weight (kg) / [height (m)]2</description>
          <units>weight (kg) / [height (m)]2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cystic fibrosis related diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Cystic fibrosis related diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-cystic fibrosis related diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA)</title>
        <description>Change from baseline Day 0 to Day 90 of erythrocyte tissue composition % of the omega-3 index</description>
        <time_frame>Day 0 to Day 90</time_frame>
        <population>Intent to treat population = 39 subjects who received at least one exposure to RELiZORB. Analysis group is 38 due to one subject discontinuing prior to Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>RELiZORB Cartridge With Standard Enteral Formula</title>
            <description>Patients with exocrine pancreatic insufficiency, age 5 and older, all sexes who have an enteral feeding a minimum of 4 times per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA)</title>
          <description>Change from baseline Day 0 to Day 90 of erythrocyte tissue composition % of the omega-3 index</description>
          <population>Intent to treat population = 39 subjects who received at least one exposure to RELiZORB. Analysis group is 38 due to one subject discontinuing prior to Visit 3.</population>
          <units>percentage of omega-3 composition</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unanticipated Adverse Device Effects (UADE)</title>
        <description>A UADE is analogous to a serious adverse event (SAE), defined as an AE, occurring at any exposure to the therapeutic agent, that results in any of the following outcomes: death, life-threatening AE, inpatient hospitalization or prolonged existing hospitalization, a persistent or significant disability or incapacity or a congenital anomaly/birth defect.</description>
        <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days with additional 30 days of follow up.</time_frame>
        <population>Total ITT population (n=39)</population>
        <group_list>
          <group group_id="O1">
            <title>RELiZORB Treatment Period (Day 0 - Day 90)</title>
            <description>All subjects who entered the RELiZORB Treatment period and received at least one treatment with the study device. 39 subjects entered treatment period of EF with RELiZORB.</description>
          </group>
        </group_list>
        <measure>
          <title>Unanticipated Adverse Device Effects (UADE)</title>
          <description>A UADE is analogous to a serious adverse event (SAE), defined as an AE, occurring at any exposure to the therapeutic agent, that results in any of the following outcomes: death, life-threatening AE, inpatient hospitalization or prolonged existing hospitalization, a persistent or significant disability or incapacity or a congenital anomaly/birth defect.</description>
          <population>Total ITT population (n=39)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with at least one UADE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, Thoracic, and Mediastinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Plasma Concentration Total DHA+EPA</title>
        <description>Changes in plasma concentration total DHA+EPA from baseline (Day 0 to Day 90).</description>
        <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
        <population>All subjects who entered the RELiZORB Treatment period, received at least one treatment with the study device and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>RELiZORB Treatment Period (Day 0 - Day 90)</title>
            <description>All subjects who entered the treatment period and received at least one exposure to RELiZORB.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Plasma Concentration Total DHA+EPA</title>
          <description>Changes in plasma concentration total DHA+EPA from baseline (Day 0 to Day 90).</description>
          <population>All subjects who entered the RELiZORB Treatment period, received at least one treatment with the study device and completed the study.</population>
          <units>percentage of total plasma concentration</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.73" lower_limit="69.50" upper_limit="117.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Composition (%) of DHA</title>
        <description>Changes over time in erythrocyte composition (%) for total DHA in ITT population (n=39)</description>
        <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
        <population>ITTT</population>
        <group_list>
          <group group_id="O1">
            <title>RELiZORB Treatment Period (Day 0 - Day 90)</title>
            <description>All subjects who entered the RELiZORB Treatment period and received at least one treatment with the study device. 39 subjects entered treatment period of EF with RELiZORB.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Composition (%) of DHA</title>
          <description>Changes over time in erythrocyte composition (%) for total DHA in ITT population (n=39)</description>
          <population>ITTT</population>
          <units>percentage of RBC composition</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" lower_limit="2.74" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Composition (%) of EPA</title>
        <description>Changes over time in erythrocyte composition (%) for EPA in ITT population</description>
        <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RELiZORB Treatment Period (Day 0 - Day 90)</title>
            <description>All subjects who entered the treatment period and received at least one exposure to RELiZORB.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Composition (%) of EPA</title>
          <description>Changes over time in erythrocyte composition (%) for EPA in ITT population</description>
          <units>percentage of RBC composition</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.32" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Composition (%) Ratio of n6/n3 Fatty Acids</title>
        <description>Change from baseline to Day 90 in n6/n3 ratio in erythrocytes</description>
        <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RELiZORB Treatment Period (Day 0 - Day 90)</title>
            <description>All subjects who entered the treatment period and received at least one exposure to RELiZORB.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Composition (%) Ratio of n6/n3 Fatty Acids</title>
          <description>Change from baseline to Day 90 in n6/n3 ratio in erythrocytes</description>
          <units>percentage of RBC composition</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" lower_limit="-2.94" upper_limit="-2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Composition (%) Ratio of n6/n3 Fatty Acids.</title>
        <description>Change over time in n6/n3 ratio in plasma in the ITT population</description>
        <time_frame>RELiZORB Treatment Period (Day 0-Day 90): 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RELiZORB Treatment Period (Day 0 - Day 90)</title>
            <description>All subjects who entered the treatment period and received at least one exposure to RELiZORB.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Composition (%) Ratio of n6/n3 Fatty Acids.</title>
          <description>Change over time in n6/n3 ratio in plasma in the ITT population</description>
          <units>percentage of total plasma concentration</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.29" lower_limit="-7.85" upper_limit="-4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>GI Symptoms</title>
        <description>GI symptoms recorded in GI diaries by subject and/or caregiver.</description>
        <time_frame>Observation, Baseline and RELiZORB Treatment periods (Day -14 to Day 90): 104 days with additional 30 days of follow up.</time_frame>
        <population>All subjects who entered the RELiZORB Treatment Period and received at least one treatment with RELiZORB.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>All subjects who entered the RELiZORB Treatment period and received at least one treatment with the study device. 39 subjects entered treatment period of EF with RELiZORB.</description>
          </group>
        </group_list>
        <measure>
          <title>GI Symptoms</title>
          <description>GI symptoms recorded in GI diaries by subject and/or caregiver.</description>
          <population>All subjects who entered the RELiZORB Treatment Period and received at least one treatment with RELiZORB.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected and reported for 14 days during the Observation and Run-in periods. Adverse event data collected and reported for 120 days for the RELiZORB period.</time_frame>
      <desc>Adverse event data were collected from study entry at day -14 to end of study (Day -14 through 90). Follow up of events present at end of study/termination continued for an additional 30 days after completion of study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Observation and Run-in Period (Day -14 to Day -1)</title>
          <description>This 14 day period was comprised of 7 day Observation period followed by 7 day Run-in period. 44 subjects were enrolled of which 39 proceeded to treatment period of EF with RELiZORB.</description>
        </group>
        <group group_id="E2">
          <title>RELiZORB Treatment Period (Day 0 - Day 90)</title>
          <description>Safety population is defined as all subjects who entered the RELiZORB Treatment period and received at least one treatment with the study device. 39 subjects entered treatment period of EF with RELiZORB.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary function decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vitamin D decrease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication by the PI of any data from this study is strictly prohibited without consent from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Patient GI symptom diary: recall method using unvalidated tool. Patients were allowed to eat normal diet during the day, hence the amount of LCPUFA that was measured in the plasma is not the sole reflection of the device use only.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Madhumalli (&quot;Molly&quot;) Sarkar, MD, PhD, Head of Clinical Development</name_or_title>
      <organization>Alcresta Therapeutics, Inc.</organization>
      <phone>617 431 8866</phone>
      <email>msarkar@alcresta.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

